{"protocolSection": {"identificationModule": {"nctId": "NCT00837967", "orgStudyIdInfo": {"id": "D589LC00003"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Investigate the Safety and Efficacy of High Dose of Symbicort\u00ae SMART in Japanese Patients", "officialTitle": "A Comparison of Tolerability of 10 Inhalations of Symbicort\u00ae Turbuhaler\u00ae 160/4.5 \u03bcg and 10 Inhalations of Terbutaline Turbuhaler\u00ae 0.4 mg on Top of Symbicort\u00ae Turbuhaler\u00ae 160/4.5 \u03bcg 1 Inhalation Bid, Randomized, Double-blind, Cross Over, Phase III Study in Japanese Adults Asthma Patients"}, "statusModule": {"statusVerifiedDate": "2012-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-01"}, "primaryCompletionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-02-05", "studyFirstSubmitQcDate": "2009-02-05", "studyFirstPostDateStruct": {"date": "2009-02-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-07-05", "resultsFirstSubmitQcDate": "2012-08-27", "resultsFirstPostDateStruct": {"date": "2012-08-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-08-27", "lastUpdatePostDateStruct": {"date": "2012-08-29", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of the study is to compare the tolerability of Symbicort\u00ae Turbuhaler\u00ae 160/4.5 \u03bcg 10 inhalations with terbutaline Turbuhaler\u00ae 0.4 mg 10 inhalations for 3 days on top of Symbicort\u00ae Turbuhaler\u00ae 160/4.5 \u03bcg 1 inhalation twice a day (bid) in adult asthma patients."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Symbicort Turbuhaler"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 25, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "First Symbicort, then Terbutaline", "type": "EXPERIMENTAL", "description": "Symbicort Turbuhaler 160/4.5\u03bcg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days", "interventionNames": ["Drug: Symbicort Turbuhaler", "Drug: Terbutaline Turbuhaler"]}, {"label": "First Turbuhaler, then Symbicort", "type": "EXPERIMENTAL", "description": "Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5\u03bcg for 3 days,", "interventionNames": ["Drug: Symbicort Turbuhaler", "Drug: Terbutaline Turbuhaler"]}], "interventions": [{"type": "DRUG", "name": "Symbicort Turbuhaler", "description": "160/4.5\u03bcg for 3 days", "armGroupLabels": ["First Symbicort, then Terbutaline", "First Turbuhaler, then Symbicort"]}, {"type": "DRUG", "name": "Terbutaline Turbuhaler", "description": "0.4 mg for 3 days", "armGroupLabels": ["First Symbicort, then Terbutaline", "First Turbuhaler, then Symbicort"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Adverse Events", "description": "Total number of adverse events", "timeFrame": "3 days"}, {"measure": "Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "timeFrame": "up to 740 min after start dosing for each treatment day"}, {"measure": "Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "timeFrame": "up to 140 min after start dosing for each treatment day"}, {"measure": "Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "timeFrame": "up to 740 min after start dosing for each treatment day"}, {"measure": "Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "timeFrame": "up to 740 min after start dosing for each treatment day"}, {"measure": "Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "timeFrame": "up to 740 min after start dosing for each treatment day"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures\n* A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006 definition\n* FEV1\\> 70% of predicted normal value pre-bronchodilator\n\nExclusion Criteria:\n\n* Having a known or suspected allergy to study therapy (active drugs or additive)\n* Having a known clinical history of hypertension, relevant arrhythmias or other heart disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart failure\n* Having been treated with oral, parenteral or rectal glucocorticoids within 4 weeks, or with depot parenteral glucocorticoids within 3 months\n* Respiratory infection significantly affecting the asthma, as judged by the investigator within 4 weeks", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "maximumAge": "65 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Tomas Andersson, MD", "affiliation": "AstraZeneca R&D Lund", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Ibaragi", "country": "Japan"}, {"facility": "Research Site", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}]}, "referencesModule": {"references": [{"pmid": "22024920", "type": "DERIVED", "citation": "Saito T, Hasunuma T. Safety and tolerability of high-dose budesonide/formoterol via Turbuhaler(R) in Japanese patients with asthma: a randomized, double-blind, crossover, active comparator-controlled, phase III study. Clin Drug Investig. 2012 Jan 1;32(1):51-61. doi: 10.2165/11595440-000000000-00000."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Patients recruited from 2 hospitals in Japan between January 2009 and July 2009. 28 patients enrolled; 25 patients randomized, 3 patients were not randomized (1 due to incorrect enrollment and 2 due to adverse event)", "groups": [{"id": "FG000", "title": "Symbicort First, Then Terbutaline", "description": "Symbicort Turbuhaler 160/4.5\u03bcg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days"}, {"id": "FG001", "title": "Terbutaline First, Then Symbicort", "description": "Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5\u03bcg for 3 days,"}], "periods": [{"title": "First Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout Period of 7 - 14 Days", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Second Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Study Participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "25"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "44.3", "spread": "14.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "15"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Adverse Events", "description": "Total number of adverse events", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "adverse events", "timeFrame": "3 days", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Turbuhaler 160/4.5\u03bcg"}, {"id": "OG001", "title": "Terbutaline", "description": "Terbutaline Turbuhaler 0.4 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "24"}]}]}]}, {"type": "PRIMARY", "title": "Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mEq/L", "timeFrame": "up to 740 min after start dosing for each treatment day", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Turbuhaler 160/4.5\u03bcg"}, {"id": "OG001", "title": "Terbutaline", "description": "Terbutaline Turbuhaler 0.4 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.01", "spread": "0.25"}, {"groupId": "OG001", "value": "3.88", "spread": "0.26"}]}]}]}, {"type": "PRIMARY", "title": "Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dLiters", "timeFrame": "up to 140 min after start dosing for each treatment day", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Turbuhaler 160/4.5\u03bcg"}, {"id": "OG001", "title": "Terbutaline", "description": "Terbutaline Turbuhaler 0.4 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "121.1", "spread": "20.3"}, {"groupId": "OG001", "value": "129.5", "spread": "22.0"}]}]}]}, {"type": "PRIMARY", "title": "Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ms", "timeFrame": "up to 740 min after start dosing for each treatment day", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Turbuhaler 160/4.5\u03bcg"}, {"id": "OG001", "title": "Terbutaline", "description": "Terbutaline Turbuhaler 0.4 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "411.71", "spread": "15.07"}, {"groupId": "OG001", "value": "414.33", "spread": "14.04"}]}]}]}, {"type": "PRIMARY", "title": "Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "up to 740 min after start dosing for each treatment day", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Turbuhaler 160/4.5\u03bcg"}, {"id": "OG001", "title": "Terbutaline", "description": "Terbutaline Turbuhaler 0.4 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "115.3", "spread": "6.3"}, {"groupId": "OG001", "value": "114.9", "spread": "8.0"}]}]}]}, {"type": "PRIMARY", "title": "Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)", "description": "The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/min", "timeFrame": "up to 740 min after start dosing for each treatment day", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Turbuhaler 160/4.5\u03bcg"}, {"id": "OG001", "title": "Terbutaline", "description": "Terbutaline Turbuhaler 0.4 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "70.0", "spread": "6.6"}, {"groupId": "OG001", "value": "74.1", "spread": "7.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Of 25 patients in safety analysis set, 2 patients did not receive terbutaline due to adverse events lead to discontinuation. Therefore, data from 25 patients for Symbicort and 23 patients for terbutaline were used for the safety evaluation.", "eventGroups": [{"id": "EG000", "title": "Symbicort", "description": "Symbicort Turbuhaler 160/4.5\u03bcg for 3 days", "seriousNumAffected": 0, "seriousNumAtRisk": 25, "otherNumAffected": 7, "otherNumAtRisk": 25}, {"id": "EG001", "title": "Terbutaline", "description": "Terbutaline Turbuhaler 0.4 mg for 3 days", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 15, "otherNumAtRisk": 23}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 23}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 23}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 23}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 23}]}, {"term": "Blood Pressure Decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 23}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000013726", "term": "Terbutaline"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000013566", "term": "Sympathomimetics"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M16496", "name": "Terbutaline", "asFound": "Temodar", "relevance": "HIGH"}, {"id": "M21711", "name": "Budesonide", "relevance": "LOW"}, {"id": "M304", "name": "Formoterol Fumarate", "relevance": "LOW"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}]}}, "hasResults": true}